Renna sells ITEK 11.03: Therefore, I suspect that the overall top-line readout is substantially de-risked.

On the other, the fact that SYN-004 has already demonstrated an ability to degrade target bacteria in the gut suggests that efficacy results are somewhat de-risked. The form stated that 4 of the 12 patients participating in the study expressed efficacy and safety outcomes that are consistent with findings from Phase 1a and Phase 1b studies of the treatment. However, those who focus strictly on Trimesta miss out on the real opportunity that lies ahead for SYN. That is to say that the data demonstrates that the drug produces statistically significant cognitive improvements expressed in the clinical outcomes of the study. The outcome of the upcoming data readout is entirely uncertain, and we do not intend to insert our opinion about the data other than to reiterate that we are cautiously optimistic that the data will be positive.


Christeen:
Moreover, we would prefer to see SYN partner with TEVA since the latter is proficient in this difficult-to-treat indication of MS.

Dodie:
For Teva, licensing and/or acquiring Trimesta, which is administered in conjunction with Copaxone, are viable options to improve the blockbuster success of Copaxone.

Lorelei:
For one, the company is expected to deliver a top-line readout for the MRI data, which, if positive, would likely solidify a partnership for Trimesta and bring instant value to shareholders.

Hilda:
We believe that investors are positioning for multiple value-driving catalysts that could come to fruition at any point later this month or early next.

John:
The stock has made a substantial recovery to the low $3s, and is quickly emerging as a breakout play.

Joie:
Our point is, nothing about PFE changed from a fundamental perspective before and after this technical event, and I believe the same can be said about Synthetic.

Thersa:
Even Pfizer (NYSE: PFE ), the biggest pharmaceutical company in the world, tanked 20% last month in intraday trading before recovering.

Ayesha:
While this is unsettling at first glance, we remain of the opinion that the loss in shareholder value was strictly emotional.

Waltraud:
We expect to ride our existing speculative positions through the foreseeable turmoil in the general market.

Kaitlin:
These Vanguard products also happen to be offered as commission-free ETFs on TD Ameritrade, which makes them suitable for the average retirement account.

Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
//stockhand.net/us/?q=nasdaq%3Aitek&id=517450